Application of pantoprazole in preparation of enhancer for MSLN-CAR-T cell treatment of brain metastatic tumor

By using pantoprazole as an enhancer in MSLN-CAR-T cell therapy, the MSLN protein expression and the killing ability of CAR-T cells were improved, and the problem of insufficient efficacy of MSLN-CAR-T cells in the treatment of brain metastases was solved. It significantly prolongs the patient's survival time and provides a new approach for CAR-T cell therapy.

CN119055648APending Publication Date: 2024-12-03THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411308953.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The efficacy of existing MSLN-CAR-T cells in the treatment of brain metastases is limited, and it is urgent to explore enhancers to improve their efficacy.

Method used

Pantoprazole as an enhancer, combined with MSLN-CAR-T cells to treat brain metastases, and by increasing MSLN protein expression, especially on cell membrane, it reduces the heterogeneity of MSLN target antigen expression and improves CAR-T cells by increasing MSLN protein expression, especially on cell membranes. homing ability and lethality.

Benefits of technology

It significantly improves the killing ability and homing ability of MSLN-CAR-T cells, extends the survival time of patients, and provides new ideas and clinical experimental basis for CAR-T cell treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055648A_ABST
    Figure CN119055648A_ABST
Patent Text Reader

Abstract

The invention discloses an application of pantoprazole in preparation of a reinforcing agent for treating brain metastases by MSLN-CAR-T cells, and the pantoprazole is used for treatment before treatment by the MSLN-CAR-T cells, so that MSLN protein expression, especially expression on cell membranes, is improved, heterogeneity of MSLN target antigen expression is reduced, and homing ability and killing ability of the MSLN-CAR-T cells are improved. A new thought is provided for treating solid tumors through CAR-T cells, and an earlier-stage foundation is laid for related clinical experiments.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of tumor treatment, and in particular to the use of pantoprazole in the preparation of an enhancer for MSLN-CAR-T cell treatment of brain metastases. Background Art

[0002] With the improvement of diagnosis and treatment technology, early detection and early treatment of cancer have prolonged the life expectancy of patients, but the incidence of brain metastasis has increased year by year. Brain metastasis usually occurs in patients with lung cancer, breast cancer and melanoma, with an incidence of 40%-50%, 20% and 10%-20% respectively. At present, the treatment options for brain metastases include surgery, whole brain radiotherapy, stereotactic radiosurgery and systemic drug therapy, but the efficacy is limited, and new treatment options are urgently needed.

[0003] Chimeric antigen receptor (CAR)-T cell immunotherapy has shown encouraging results in different types of cancer and has been approved for the treatment of hematological malignancies. In a preclinical study, HER2-CAR-T cells were administered intraventricularly in a mouse model of breast cancer brain metastasis, and the results showed regression of multiple brain metastases and meningeal metastases and prolonged overall survival. Based on this preclinical study, a phase I clinical trial of HER2-CAR-T cells for the treatment of recurrent brain / meningeal metastases is underway (NCT03696030). This brings new hope to the treatment of brain metastases.

[0004] MSLN is a glycosylated phosphatidylinositol-anchored protein that is usually present in small amounts on the surface of mesothelial cells in the pleura, pericardium, peritoneum, and theca (male). Currently, MSLN has been found to be overexpressed in a variety of cancers, including malignant mesothelioma, ovarian cancer, breast cancer, pancreatic cancer, lung cancer, gastric cancer, cervical cancer, uterine serous carcinoma, and bile duct cancer. Unfortunately, analysis of published studies on MSLN-CAR-T cell therapy for solid tumors showed that MSLN-CAR-T cell monotherapy had good safety but failed to exert significant clinical efficacy beyond disease stabilization. Therefore, it is of great clinical significance to explore the mechanism behind the poor clinical treatment effect of MSLN-CAR-T cells and propose targeted measures.

[0005] Clinically, proton pump inhibitors are widely used to treat a variety of digestive system diseases such as peptic ulcers and gastroesophageal reflux disease. The results of many clinical studies have shown that pretreatment with proton pump inhibitors combined with metronomic chemotherapy can inhibit autophagy, reverse the drug resistance of stubborn tumors, and induce chemotherapy sensitization of a variety of solid tumors such as osteosarcoma, breast cancer and digestive tract tumors. Proton pump inhibitors include pantoprazole, omeprazole, lansoprazole, rabeprazole, esomeprazole, etc., which can pass through the blood-brain barrier. Among them, pantoprazole is a third-generation proton pump inhibitor, which is more stable than similar drugs in a weak acid environment. After being activated, it only binds to two sites on the activation site of the proton pump (while omeprazole and lansoprazole show binding to more sites on the activation site), which reflects the high selectivity of binding to the proton pump at the molecular level. Pantoprazole has a weak inhibitory effect on cytochrome P450 enzymes, and can be metabolized through the second enzyme system, is not prone to drug interactions, and is safer when used in combination with other drugs. Whether pantoprazole can improve the efficacy of MSLN-CAR-T cells in the treatment of brain metastases needs further exploration. Summary of the invention

[0006] In view of this, one of the objects of the present invention is to provide an application of pantoprazole in the preparation of an enhancer for MSLN-CAR-T cells in the treatment of brain metastases; a second object of the present invention is to provide an application of pantoprazole combined with MSLN-CAR-T cells in the preparation of a drug for the treatment of brain metastases.

[0007] In order to achieve the above object, the present invention provides the following technical solutions: Application of pantoprazole in the preparation of enhancers for MSLN-CAR-T cell therapy of brain metastases.

[0008] Preferably, the brain metastasis is malignant mesothelioma, ovarian cancer, breast cancer, pancreatic cancer, lung cancer, gastric cancer, cervical cancer, uterine serous carcinoma or bile duct cancer.

[0009] Application of pantoprazole combined with MSLN-CAR-T cells in the preparation of drugs for the treatment of brain metastases.

[0010] Preferably, the application of the present invention is to use an effective amount of pantoprazole every day one week before MSLN-CAR-T cell therapy.

[0011] The beneficial effect of the present invention is that: the present invention provides the use of pantoprazole in the preparation of an enhancer for MSLN-CAR-T cell therapy of brain metastases, provides a new use for pantoprazole, and improves the homing ability and killing ability of MSLN-CAR-T cells by increasing the expression of MSLN protein, especially on the cell membrane, reducing the heterogeneity of MSLN target antigen expression. It provides a new idea for CAR-T cell therapy of solid tumors and lays a preliminary foundation for related clinical trials. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration: Figure 1 This is the fluorescence intensity diagram of pantoprazole combined with MSLN-CAR-T cells in the treatment of triple-negative breast cancer brain metastases.

[0013] Figure 2 This is a quantitative analysis of the fluorescence intensity of pantoprazole combined with MSLN-CAR-T cells in the treatment of triple-negative breast cancer brain metastases.

[0014] Figure 3 This is the survival analysis of pantoprazole combined with MSLN-CAR-T cells in the treatment of triple-negative breast cancer brain metastases.

[0015] Figure 4 Representative immunohistochemical images showing that pantoprazole increases the expression of MSLN protein in triple-negative breast cancer brain metastasis cells.

[0016] Figure 5 This is the fluorescence intensity diagram of pantoprazole combined with MSLN-CAR-T cells in the treatment of brain metastases of non-small cell lung cancer.

[0017] Figure 6 This is a quantitative analysis of the fluorescence intensity of pantoprazole combined with MSLN-CAR-T cells in the treatment of brain metastases from non-small cell lung cancer.

[0018] Figure 7 This is a survival analysis chart of pantoprazole combined with MSLN-CAR-T cells in the treatment of brain metastases from non-small cell lung cancer.

[0019] Figure 8 Representative immunohistochemical images showing that pantoprazole increases the expression of MSLN protein in non-small cell lung cancer brain metastasis cells. DETAILED DESCRIPTION

[0020] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0021] In the present invention, pantoprazole was purchased from Selleck, USA (item number: S5608); MSLN-CAR plasmid was purchased from ICARTAB, China (item number: LIC012A); T cells were obtained from healthy donors of the blood transfusion department of the First Affiliated Hospital of Army Medical University; MSLN antibody was purchased from abcam, USA (activation: ab133489); immunohistochemistry kit was purchased from Dako, Denmark (item number: K5007); NOG mice were purchased from Vital River Company and raised in the Animal Experiment Center of the First Affiliated Hospital of Army Medical University.

[0022] Pantoprazole combined with MSLN-CAR-T cells inhibits brain metastases of triple-negative breast cancer. The specific steps are as follows: A. Construction of triple-negative breast cancer brain transplant tumor model using cranial stereotaxic instrument: (1) Collect tumor cells with good growth status and adjust the cell density to 2×10 4 Place the cells on ice and bring to the animal experiment center.

[0023] (2) Anesthetize the mice intraperitoneally with an appropriate amount of chloral hydrate according to their body weight (female NOG mice, 18-22 g).

[0024] (3) After successful anesthesia, fix the mouse (prone position) with a cranial stereotaxic apparatus, disinfect the surgical area with an alcohol cotton ball, cut the skin on the mouse's head, drill a hole in the skull (position: 1.5 mm to the right of the anterior fontanelle and 1.5 mm forward), and inject 10 μL of the cell suspension into the mouse's skull using a microinjector to a needle insertion depth of 2.5 mm.

[0025] (4) Inject cells slowly and at a steady speed. Leave the syringe for 2 minutes after injection and then slowly remove the syringe. Disinfect the wound with an alcohol cotton ball and suture it.

[0026] (5) Return the mice to their cages and observe them closely, then select tumor-bearing mice as experimental mice.

[0027] B. The mice were divided into control group, pantoprazole group, MSLN-CAR-T cell group and pantoprazole combined with MSLN-CAR-T cell group; C. Pantoprazole 6 mg / kg was given intraperitoneally once a day starting on the fourth day of tumor bearing for 1 week; D. MSLN-CAR-T cells were intratumorally administered on the seventh day of tumor bearing; E. Use small animal in vivo imaging to observe changes in tumor fluorescence intensity (representing tumor size) ( Figure 1 and Figure 2), and found that compared with the other three groups, the tumor fluorescence intensity of the pantoprazole combined with MSLN-CAR-T cell group was reduced; the survival analysis results showed that the survival time of the pantoprazole combined with MSLN-CAR-T cell group was 1 times longer than that of the MSLN-CAR-T cell group ( Figure 3 ); F. Tumor tissues of mice in the MSLN-CAR-T cell group and the pantoprazole combined with MSLN-CAR-T cell group were subjected to MSLN immunohistochemical staining. The results showed that the expression of MSLN protein in the pantoprazole combined with MSLN-CAR-T cell group was significantly increased ( Figure 4 ).

[0028] The above results indicate that the use of pantoprazole increases the expression of MSLN protein, especially on the cell membrane, reduces the heterogeneity of MSLN target antigen expression, and improves the homing ability and killing ability of MSLN-CAR-T cells.

[0029] Pantoprazole combined with MSLN-CAR-T cells inhibit brain metastases of non-small cell lung cancer. The specific steps are as follows: A. A non-small cell lung cancer brain transplant tumor model was established using a cranial stereotaxic instrument (the method is the same as above); the mice were divided into a control group, a pantoprazole group, a MSLN-CAR-T cell group, and a pantoprazole combined with MSLN-CAR-T cell group; B. Pantoprazole 6 mg / kg was given intraperitoneally starting on the fourth day of tumor bearing, once a day for 1 week; C. MSLN-CAR-T cells were intratumorally administered on the seventh day of tumor bearing; D. Use small animal in vivo imaging to observe changes in tumor fluorescence intensity (representing tumor size) ( Figure 5 and Figure 6 ), and performed survival analysis ( Figure 7 ); The results showed that the tumor fluorescence intensity was reduced in the pantoprazole combined with MSLN-CAR-T cell group; the survival analysis results showed that the survival time of the pantoprazole combined with MSLN-CAR-T cell group was longer than that of the MSLN-CAR-T cell group.

[0030] E. Tumor tissues of mice in the MSLN-CAR-T cell group and pantoprazole combined with MSLN-CAR-T cell group were taken for MSLN immunohistochemical staining ( Figure 8 ), the results showed that the expression of MSLN protein was significantly increased in the pantoprazole combined with MSLN-CAR-T cell group.

[0031] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. Application of pantoprazole in the preparation of enhancers for MSLN-CAR-T cell therapy of brain metastases.

2. The use according to claim 1, Features: The brain metastasis is malignant mesothelioma, ovarian cancer, breast cancer, pancreatic cancer, lung cancer, gastric cancer, cervical cancer, uterine serous carcinoma or bile duct cancer.

3. Application of pantoprazole combined with MSLN-CAR-T cells in the preparation of drugs for the treatment of brain metastases.

4. The use according to claim 3, Features: The application is to use an effective amount of pantoprazole every day one week before MSLN-CAR-T cell treatment.

Citation Information

Cited By

  • Application of pantoprazole in preparation of enhancer for MSLN-car-t cell therapy against brain metastases

    WO2026061436A1